BAX and diffuse large B-cell lymphoma: Immunostaining of Bax in DLBCL has served as a statistically significant factor in prognosticating both overall (P = 0.0015; 3-year OS rates of 81.7% and 46.3% for Bax-positive and Bax-negative cases, respectively) and disease-free survival (P = 0.0052; 3-year DFS rates of 80.5% and 44.6% for Bax-positive and Bax-negative cases, respectively)47.